首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1896860

数位生物标记市场规模、份额和成长分析（按类型、临床实践、治疗领域、最终用户和地区划分）：产业预测（2026-2033 年）

Digital Biomarkers Market Size, Share, and Growth Analysis, By Type, By Clinical Practice, By Therapeutic Area, By End Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球数位生物标记市场规模将达到 50.2 亿美元，到 2025 年将成长至 64.7 亿美元，到 2033 年将成长至 489.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 28.8%。

全球数位生物标记市场正经历显着成长，这主要得益于远距照护服务和远端患者监护需求的不断增长。医疗技术的快速发展、创新解决方案的高普及率以及医疗费用支出的持续成长进一步推动了市场发展。分散式临床试验的投资和治疗应用的拓展是关键驱动因素，而穿戴式装置和智慧型手机的广泛应用也为此提供了有力支撑。监测呼吸、语音、体温和眼动等指标的先进技术能够实现复杂疾病的即时追踪。音频数位生物标誌物尤其展现出巨大的成长潜力。随着智慧型手机和穿戴式装置的普及，这些数位工具能够透过语音录製进行非侵入性采样，这不仅提升了患者的便利性，也推动了智慧型手錶和健身追踪器的普及。

全球数位生物标记市场驱动因素

糖尿病、高血压和心血管疾病的日益增多表明，医疗保健领域对数位生物标记的需求日益增长。这些创新工具能够提供关键讯息，使医疗保健系统能够快速回应并持续监测慢性疾病。透过促进最佳管理策略，数位生物标记有助于患者更长时间地保持健康，并减少住院次数。这不仅提高了个人的生活质量，还降低了医疗成本。因此，在对更有效的慢性疾病管理和改善患者预后的需求驱动下，全球数位生物标记市场正在蓬勃发展。

限制全球数位生物标记市场的因素

全球数位生物标记市场面临许多挑战，其中许多数位生物标记缺乏临床检验，而临床验证对于其被接受并整合到标准医疗实践中至关重要。缺乏严谨的检验引发了人们对其准确性和可靠性的担忧，阻碍了医疗专业人员对其的信任。由于医疗专业人员在决策中优先考虑实证工具，缺乏检验的数位生物标记限制了他们采用这些技术的意愿。因此，在缺乏必要的真实世界检验和疗效证明的情况下，数位生物标记的广泛接受和纳入常规治疗通讯协定仍然受到限制。

全球数位生物标记市场趋势

全球数位生物标记市场正呈现出人工智慧 (AI) 技术融合的显着趋势，这正在改变穿戴式装置和应用程式生成的健康数据的分析方式。这项进步使得透过先进的 AI 演算法处理大量患者资料成为可能，从而挖掘出传统方法可能忽略的模式和洞见。因此，市场正朝着更积极主动和个人化的医疗保健解决方案转型，以改善疾病管理并优化患者预后。利用数位生物标记的预测能力，医疗保健提供者能够提供更精准的诊断和个人化的治疗方案，有助于建立更有效率的医疗保健生态系统。

BioSensics（美国）
AliveCor（美国）
BACtrack（美国）
Eyenuk（美国）
Quibim（西班牙）
Biofourmis（美国）
Fitbit（美国）
Evidation Health（美国）
Empatica（美国）
飞利浦医疗保健（荷兰）
美敦力（爱尔兰）
Akili Interactive（美国）
苹果公司（美国）
Biotricity（美国）
Tempus（美国）
Pear Therapeutics（美国）
BioBeats（英国）
Oura Health（芬兰）
ActiGraph（美国）
科内克萨（美国）

结论与建议

简介目录

Product Code: SQMIG35G2218

Global Digital Biomarkers Market size was valued at USD 5.02 Billion in 2024 and is poised to grow from USD 6.47 Billion in 2025 to USD 48.97 Billion by 2033, growing at a CAGR of 28.8% during the forecast period (2026-2033).

The global digital biomarkers market is experiencing significant growth driven by rising demand for telecare services and remote patient monitoring. The swift advancement of healthcare technology, coupled with high adoption rates of innovative solutions and increasing healthcare spending, further boosts market momentum. Investment in decentralized clinical trials and the expansion of therapeutic applications are key factors, alongside the proliferation of wearable devices and smartphones. Advanced technologies that monitor indicators such as breathing, voice, temperature, and eye movements enable real-time tracking of complex diseases. Notably, vocal digital biomarkers show considerable potential for growth. With the widespread use of smartphones and wearables, these digital tools facilitate unobtrusive sampling through audio recordings, enhancing patient convenience while fostering the adoption of smartwatches and fitness trackers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Digital Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Biomarkers Market Segments Analysis

Global Digital Biomarkers Market is segmented by Type, Clinical Practice, Therapeutic Area, End Users and region. Based on Type, the market is segmented into Wearable, Mobile based Applications, Sensors and Others. Based on Clinical Practice, the market is segmented into Diagnostic digital biomarkers, Monitoring digital biomarkers, Predictive and Prognostic digital biomarkers and Others. Based on Therapeutic Area, the market is segmented into Cardiovascular and metabolic disorders (CVMD), Respiratory disorders, Psychiatric disorders, Sleep & Movement Disease, Neurological disorders, Musculoskeletal disorders and Others. Based on End Users, the market is segmented into Healthcare companies, Healthcare Providers, Payers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Digital Biomarkers Market

The increasing prevalence of diabetes, hypertension, and cardiovascular diseases highlights the rising need for digital biomarkers in healthcare. These innovative tools provide essential insights that enable healthcare systems to react promptly and maintain continuous monitoring of chronic conditions. By promoting optimal management strategies, digital biomarkers empower patients to maintain better health for extended durations, reducing the frequency of hospitalizations. This ultimately enhances the quality of life for individuals while simultaneously lowering healthcare costs. As a result, the global digital biomarkers market is gaining momentum, driven by the demand for more effective management of chronic diseases and improved patient outcomes.

Restraints in the Global Digital Biomarkers Market

The Global Digital Biomarkers market faces significant challenges due to the lack of clinical validation for many digital biomarkers, which is essential for their acceptance and integration into standard medical practices. This absence of rigorous research raises concerns about their accuracy and reliability, hindering trust among healthcare professionals. As medical practitioners prioritize evidence-based tools in their decision-making, the absence of validated digital biomarkers limits their willingness to adopt these technologies. Consequently, without the necessary validation and proven efficacy in real-world settings, the widespread acceptance and incorporation of digital biomarkers into routine treatment protocols remain constrained.

Market Trends of the Global Digital Biomarkers Market

The Global Digital Biomarkers market is witnessing a significant trend towards the integration of artificial intelligence (AI) technologies, transforming how health data generated from wearables and applications is analyzed. This advancement allows for the processing of vast amounts of patient data through sophisticated AI algorithms, unveiling patterns and insights that may go unnoticed by traditional methods. Consequently, the market is moving towards more proactive, personalized healthcare solutions, enhancing disease management capabilities and optimizing patient outcomes. By leveraging the predictive power of digital biomarkers, healthcare providers can deliver more accurate diagnoses and tailored treatment plans, fostering a more efficient healthcare ecosystem.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technology Analysis

Global Digital Biomarkers Market Size by Type & CAGR (2026-2033)

Market Overview
Wearable
Mobile based Applications
Sensors
Others

Global Digital Biomarkers Market Size by Clinical Practice & CAGR (2026-2033)

Market Overview
Diagnostic digital biomarkers
Monitoring digital biomarkers
Predictive and Prognostic digital biomarkers
Others

Global Digital Biomarkers Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Cardiovascular and metabolic disorders (CVMD)
Respiratory disorders
Psychiatric disorders
Sleep & Movement Disease
Neurological disorders
Musculoskeletal disorders
Others

Global Digital Biomarkers Market Size by End Users & CAGR (2026-2033)

Market Overview
Healthcare companies
Healthcare Providers
Payers
Others

Global Digital Biomarkers Market Size & CAGR (2026-2033)

North America (Type, Clinical Practice, Therapeutic Area, End Users)
- US
- Canada
Europe (Type, Clinical Practice, Therapeutic Area, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Clinical Practice, Therapeutic Area, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Clinical Practice, Therapeutic Area, End Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Clinical Practice, Therapeutic Area, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

BioSensics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AliveCor (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BACtrack (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eyenuk (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quibim (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biofourmis (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fitbit (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evidation Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Empatica (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips Healthcare (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akili Interactive (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apple Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotricity (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tempus (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pear Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioBeats (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oura Health (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ActiGraph (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koneksa (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments